What is fibrothorax?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 18, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Fibrothorax?

Fibrothorax is a condition characterized by extensive pleural fibrosis that encases the lung, restricting its expansion and causing restrictive lung function impairment. 1, 2

Definition and Pathophysiology

Fibrothorax represents the end-stage consequence of pleural inflammation where thick, inelastic fibrous tissue forms over the visceral and parietal pleura, creating a rigid "peel" that prevents normal lung expansion. 2 This fibrotic process can result from various inflammatory insults to the pleural space, with the response of pleural mesothelial cells to injury determining whether normal healing or pathologic fibrosis occurs. 2

The condition can be conceptually divided into two clinical horizons: 3

  • Pleural fibrosis - primarily involving the pleural surfaces
  • Lung parenchymal fibrosis - extending into the underlying lung tissue

Common Etiologies

The most frequent causes include: 1, 3, 2

  • Asbestos exposure - particularly in workers with prolonged occupational contact (insulators, shipyard workers, construction trades)
  • Tuberculous pleuritis - a major cause in endemic regions
  • Empyema - especially when inadequately drained or treated
  • Hemothorax - particularly when blood is not evacuated promptly
  • Uremic pleuritis - in patients with end-stage renal failure 1
  • Iatrogenic causes - including complications from ventriculopleural shunts 4

Calcification may develop within the fibrothorax and can occur on both parietal and visceral pleural surfaces, contrary to older teaching that suggested only visceral pleural involvement. 5

Clinical Presentation

Dyspnea on exertion is the predominant symptom, typically mild in most cases but present in approximately 95% of patients with diffuse pleural thickening or fibrothorax. 1 Additional features include:

  • Chest pain - present in more than half of patients, usually intermittent but constant in 9% 1
  • Restrictive ventilatory defect - found in approximately one-third of cases 1
  • Physical examination - may reveal decreased breath sounds and reduced chest wall expansion on the affected side 3

Diagnostic Approach

Diagnosis requires: 1, 3

  • Chest imaging - plain radiography showing pleural thickening with or without calcification
  • CT scanning - better delineates extent of pleural thickening and underlying lung parenchymal changes
  • Pulmonary function tests - typically demonstrate restrictive physiology with reduced lung volumes
  • Occupational/exposure history - essential for identifying asbestos-related disease, requiring documentation of exposure occurring 15+ years before presentation 1

Rapidly progressive or severe chest pain should raise immediate suspicion for either malignancy (mesothelioma, metastatic disease) or active nonmalignant pleuritis requiring tissue diagnosis. 1, 6

Important Clinical Pitfalls

  • Chronic fibrothorax may envelop a fluid-filled cavity that can become infected after prolonged latency, often associated with bronchopleural or pleurocutaneous fistula formation 5
  • Adequate pleural drainage during acute inflammatory processes is the physician's responsibility and represents the primary prevention strategy for pleural fibrosis, while patient medication compliance is more relevant for preventing primary parenchymal fibrosis 3
  • Tissue sampling in fibrothorax is challenging with standard flexible forceps, and novel techniques such as electrosurgical biopsy may be required to obtain adequate samples for distinguishing malignant from benign disease 6

Management Considerations

Treatment of established fibrothorax is primarily surgical: 1

  • Decortication - surgical removal of the fibrous peel to allow lung re-expansion
  • Lung release procedures - may improve lung function and clinical course in selected cases 1

However, these invasive interventions carry significant morbidity, particularly in elderly or frail patients with end-stage renal disease. 1 The decision for surgical intervention must weigh the restrictive physiology severity against operative risks and patient functional status.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pleural fibrosis.

Clinics in chest medicine, 2006

Research

Fibrothorax--problem, profile and prevention.

Journal of the Indian Medical Association, 1997

Research

Chronic calcified empyema.

Journal of the Canadian Association of Radiologists, 1981

Related Questions

What is fibrothorax?
What are the guidelines for diagnosing and managing fibrothorax?
What is the management rule for fibrothorax?
What are the treatment guidelines for fibrothorax?
What is the recommended treatment for fibrothorax in an otherwise healthy adult presenting with dyspnea, reduced chest expansion, and a restrictive pattern on pulmonary function testing?
What is the recommended conservative management for a patient with critical limb ischemia who is not a candidate for revascularization because of severe comorbidities, lack of suitable conduit, limited life expectancy, or a non‑viable limb?
In an adult hypertensive patient on amlodipine 5 mg daily who develops peripheral edema, how can I balance its arterial vasodilation with venodilation?
Which medications are contraindicated or should be avoided in patients with mitochondrial disease?
How should cataract be evaluated and managed in adults over 60 (including those with diabetes, long‑term steroid use, trauma or hereditary risk), covering indications for surgery, pre‑operative assessment (axial length, corneal curvature, ocular comorbidities, systemic conditions), phacoemulsification with intra‑ocular lens implantation, post‑operative regimen (topical moxifloxacin, prednisolone acetate or bromfenac, protective shield, activity restrictions, follow‑up schedule), and non‑surgical alternatives when surgery is contraindicated?
What ACE inhibitor or ARB dose should be added to a patient taking amlodipine 2.5 mg daily to counteract peripheral edema and achieve blood pressure control?
Is systemic heparin indicated for acute arterial thrombosis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.